INTRODUCTION
Thymosin a1 (Ta1), a 28-amino-acid peptide, was originally isolated from bovine thymus as a thymic hormone and is now obtained by synthetic preparation (Low et al, 1979; Wang et al, 1980) . Ta1, known for its ability as an immune adjuvant for vaccines, is in clinical trials worldwide for the treatment of hepatitis B virus, hepatitis C virus and cancer (Billich, 2002) . Studies on the molecular basis of its action have suggested that Ta1 can induce T-cell and dendritic cell (DC) maturation as well as interleukin (IL)-12 expression (Knutsen et al, 1999; Romani et al, 2004) . In addition, a recent study indicated that Ta1 upregulates expression of Toll-like receptor (TLR) 2, 5, 8 and 9, and protects mice from challenge by invasive aspergillosis in a myeloid differentiate factor 88 (MyD88)-dependent way (Romani et al, 2004) .
The canonical TLR signalling pathway includes several crucial intermediates such as MyD88, IL-1 receptor-associated kinase activator (IRAK) and tumour necrosis factor (TNF) receptorassociated factor 6 (TRAF6; Akira & Takeda, 2004) . It has been established that TLRs, on activation by their agonists, recruit MyD88, followed by bringing IRAK1 and IRAK4 to the intracellular domains of the transmembrane receptors. IRAK1 is phosphorylated by IRAK4 and then interacts with TRAF6, which is essential for nuclear factor-kB (NF-kB) activation. Typical NF-kB activation involves the IkB kinase (IKK) complex, which consists of two catalytic subunits, IKKa and IKKb, as well as the regulatory subunit IKKg. Activated IKK phosphorylates IkB, which immediately undergoes degradation and subsequently liberates NF-kB. Several studies have suggested that activation of NF-kB by TRAF6 involves atypical protein kinase C (aPKC; PKCi and PKCz) as well as the adaptor protein p62 (Sanz et al, 2000; Leitges et al, 2001; Duran et al, 2003) . As aPKC associates with IKK (Sanz et al, 1999) , it is likely that, on IL-1 stimulation, TRAF6 forms a complex with p62 and aPKC, which in turn activates IKK. This has been shown by the overexpression of dominant negative (dn) mutants of either PKCi or PKCz, which block IKK and NF-kB activation . Moreover, genetic evidence shows that activation of IKK and NF-kB by IL-1, lipopolysaccharide (LPS) and TNFa is largely impaired in PKCz-deficient lung cells (Leitges et al, 2001) . Interestingly, in PKCz-deficient mouse embryo fibroblasts (MEFs), activation of NF-kB, but not IKK, by IL-1 is inhibited (Leitges et al, 2001) , suggesting a redundant role of PKCi in this pathway.
We investigated signalling pathways responsive to Ta1 that lead to induction of IL-6. We obtained evidence showing that an essential pathway that triggers NF-kB activation by Ta1 is dependent on IKKb, which requires TRAF6 and aPKC. We showed that, on Ta1 stimulation, TRAF6 is activated and forms a signalsome that contains TRAF6, p62 and PKCi/z. Therefore, our study shows that IKKb and TRAF6 are decisive components in the Ta1-induced immune response.
RESULTS

Ta1 induces production of IL-6 in vitro and in vivo
As Ta1 has been shown to induce IL-12 expression (Romani et al, 2004) , we investigated whether Ta1 directly activates macrophages to produce IL-6. Bone-marrow-derived macrophages (BMDMs) were treated with different amounts of Ta1 for 24 h and supernatant samples were assessed. IL-6 secretion was induced by Ta1 at a concentration of 25 ng/ml and reached higher levels at 100 ng/ml (Fig 1A) . However, Ta1 at a much higher concentration (e.g. 4 mg/ml) did not further increase, but instead inhibited IL-6 secretion (data not shown). Ta1 also stimulated BMDMs to produce IL-12 (Fig 1C) . In contrast, scrambled Ta1 (sTa1; same amino acids as Ta1, but in an altered primary sequence) failed to induce IL-6 and IL-12 in BMDMs (Fig 1B,C) .
The induction of IL-6 and IL-12 by Ta1 is associated with increases in messenger RNA. BMDMs were treated with Ta1 and levels of IL-6 and IL-12 mRNA were examined by reverse transcription-PCR (RT-PCR) analysis. IL-6 and IL-12 mRNA levels were detected after a 2 h incubation with Ta1 and decayed after 6 h (Fig 1D) . Furthermore, mice were injected with Ta1 or phosphate-buffered saline (PBS), and the levels of IL-6 and IL-12 mRNA in the liver were analysed. IL-6 and IL-12 mRNA levels increased 4 h after injection in Ta1-but not PBS-treated livers (Fig 1E; data not shown). Thus, Ta1 can induce IL-6 and IL-12 production in both BMDMs and mice.
IKKb is essential for cytokine induction by Ta1
Ta1 triggers NF-kB activation (Romani et al, 2004) , although the pathway of activation has not yet been explained. Therefore, we investigated whether Ta1 activates IKK, which is known to be essential for activation of NF-kB. Incubation of BMDMs with Ta1 resulted in strong activation of IKK (Fig 2A) . As Ta1 is derived from pro-thymosin a1 (Sarandeses et al, 2003) and is found to be circulating in the blood (Welch et al, 1988) , we reasoned that effectors for Ta1 activity should not be limited to immune cells. Therefore, we examined the responses of several different types of cell to Ta1. As we expected, Ta1 activated IKK in MEFs (Fig 2A, right panel) , embryonic stem (ES) cells, NIH-3T3 cells and human T-lymphocyte Motl4 cells (data not shown). In contrast, sTa1 induced minimal activation of IKK in MEFs (Fig 2A, right panel) . (A) Bone-marrow-derived macrophages (BMDMs) were treated with indicated amounts of Ta1 for 24 h and the level of IL-6 was assessed by enzyme-linked immunosorbent assay. Levels of IL-6 (B) and IL-12 (C) in BMDMs treated with Ta1 (100 ng/ml) or sTa1 (100 ng/ml) were determined. (D) Levels of IL-6 and IL-12 mRNA in BMDMs treated with Ta1 (100 ng/ml) for indicated durations were assessed by RT-PCR. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (E) Mice were injected intravenously with Ta1 (10 mg per mouse). After 3 h, mice were killed and total RNA was isolated using Trizo (Invitrogen). The levels of IL-6 and IL-12 mRNA in the liver were determined by RT-PCR.
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Our previous studies suggested that IKKb is crucial for polynucleotide-triggered activation of IKK and NF-kB and subsequent immune responses (Chu et al, 1999 (Chu et al, , 2000 . Thus, we proposed that IKKb also has a pivotal role in the activation of IKK and NF-kB, as well as induction of cytokines, by Ta1. To test this possibility, we decided to use Tnfr1 À/À Ikk þ /À (referred to as 'IKKb heterozygous') mice to generate Tnfr1 À/À Ikkb À/À (referred to as 'IKKb-deficient') mice (Chu et al, 2000; Senftleben et al, 2001) . BMDMs from Tnfr1 À/À and IKKb-deficient mice were then isolated to determine the role of IKKb in the Ta1-driven NF-kB activation. Incubation of Tnfr1 À/À BMDMs with Ta1 resulted in strong activation of IKK and NF-kB ( Fig 2B) . In contrast, the loss of IKKb severely impaired activation of IKK by Ta1 and, as a result, Ta1 stimulation of NF-kB activity was almost abolished in IKKbdeficient BMDMs (Fig 2B) . In line with a previous report (Chu et al, 2000) , activation of IKK and NF-kB by LPS was largely reduced in IKKb-deficient cells ( Fig 2B) . As a control, we measured p38 kinase activity in Tnfr1 À/À and IKKb-deficient BMDMs, and found that both were equally responsive to Ta1 in activating p38 (data not shown).
We next determined whether IKKb is crucial for IL-6 and IL-12 induction by Ta1. Heterozygous and IKKb-deficient BMDMs were incubated with Ta1 for 24 h and the levels of IL-6 and IL-12 were determined. The loss of IKKb almost abolished induction of IL-6 by Ta1 compared with wild-type (WT) controls (Fig 2C) . However, IL-12 was not detected in either heterozygous or IKKb-deficient BMDMs under our experimental conditions (data not shown). As it is difficult to generate enough IKKb-deficient mice for experiments, and Ta1 is able to activate MEFs (Fig 2A) , we examined activation of IKK by Ta1 in IKKb-deficient MEFs. As we expected, activation of IKK in IKKb-deficient MEFs was largely impaired (Fig 2D) . To examine further whether induction of IL-6 and IL-12 by Ta1 occurs at the level of transcription, we performed RT-PCR. As shown in Fig 2E, induction of IL-6 and IL-12 mRNA was not observed in IKKb-deficient MEFs. Taken together, our data suggest that IKKb is essential for the activation of IKK and NF-kB, and for induction of IL-6 and IL-12 by Ta1.
Activation of IKK involves aPKC
A previous study indicated that Ta1 activates PKC in thymocytes (Baumann et al, 1997) . However, it is not clear which class of PKCs is activated and what role PKC has in the Ta1 pathway. To resolve these issues, we first investigated whether Ta1 activates aPKC in MEFs. As shown in Fig 3A, aPKC activation was induced by Ta1 after a 7.5 min incubation and its activity reached a maximal level around 1 h ( Fig 3A) . Next, we explored the possibility of involvement of aPKC in the activation of IKK by Ta1 using a specific aPKC inhibitor, Go6983. At a concentration of 120 nM, Go6983 inhibited activation of IKK by Ta1, but not by TNFa (Fig 3B) . At the same concentration, Go6983 had no effect on activation of either c-Jun N-terminal kinase or extracellular signal-regulated kinase 1/2 by Ta1 (data not shown). To verify the involvement of PKCz in activation of IKK, we transfected PKCz short interfering RNA (siRNA) and mock siRNA into 3T3-like MEFs. As shown in Fig 3C, lower levels of phosphorylation of PKCz and IKKa/b by Ta1 were observed in cells transfected with PKCz siRNA compared with mock transfectants. As a result, activation of IKK by Ta1 was impaired in PKCz siRNA transfectants (Fig 3C) . Taken together, these experimental After 24 h, cells were treated with Ta1 (100 ng/ml) for 1 h. Cell lysates were prepared and the IKKb kinase complex was immunoprecipitated using an anti-HA antibody followed by a kinase assay to measure IKK KA. (E) Wild-type (WT) and TRAF6-deficient cells were treated with Ta1 (100 ng/ml), TNFa (10 min, 20 ng/ml) or lipopolysaccharide (LPS; 30 min, 10 mg/ml) for indicated durations. A 100 mg portion of cell lysates was used to assess IKK KA, followed by IB analysis. (F) WT and TRAF6-deficient MEFs were treated with Ta1 for 6 h. Total RNA was isolated and then subjected to RT-PCR analysis. (G) WT and TRAF6-deficient MEFs were treated with Ta1 (100 ng/ml) and then phosphorylation of PKCi/z was assessed. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
Ta1 activates IKK and aPKC through TRAF6
A recent study suggested that MyD88 is involved in the Ta1 pathway (Romani et al, 2004) . As IRAK1 and TRAF6 act downstream to MyD88 in the TLR signalling pathway, we investigated whether MyD88, IRAK1 or TRAF6 has a role in activation of IKK by Ta1. First, we performed a transient transfection assay using dnIRAK1, dnMyD88 and dnTRAF6 expression vectors. Results in Fig 3C show that all doublenegative mutants, dnIRAK1, dnMyD88 and dnTRAF6, blocked IKK activation by Ta1. Next, we evaluated IKK activation in TRAF6-deficient MEFs. Incubation of WT cells with Ta1 strongly induced IKK activation, whereas the loss of TRAF6 severely impaired activation of IKK by Ta1 (Fig 3D) . As controls, both WT and deficient cells were similarly responsive to TNFa in activating IKK ( Fig 3D) ; activation of IKK by LPS was almost abrogated in TRAF6-deficient cells (Fig 3D) . Indeed, TRAF6 is involved in activation of IKK by Ta1, as introduction of WT TRAF6 restored activation of IKK by Ta1 in TRAF6-deficient cells (data not shown). In addition, we determined whether TRAF6 contributes to the expression of IL-6 by Ta1. As shown in Fig 3E, induction of IL-6 was largely impaired in TRAF6-deficient MEFs. As Ta1 activates both IKK and PKCi/z, we tested whether TRAF6 acts upstream of aPKC. As shown in Fig 3F, activation of PKCi/z by Ta1 was inhibited in TRAF6-deficient cells. Taken together, our results show that MyD88 and IRAK1 are involved in the activation of IKK, and that TRAF6 is crucial for the activation of IKK and PKCi/z by Ta1.
Ta1 induces formation of a TRAF6-p62-aPKC complex
We sought to determine whether TRAF6 and aPKC interact in response to Ta1. WT MEFs were treated with Ta1 and cell lysates were prepared. PKCi/z were immunoprecipitated, and co-immunoprecipitation of TRAF6 was detected by an immunoblotting (IB) analysis. Results in Fig 4A show that Ta1 triggered association of PKCi/z with TRAF6. Next, we investigated whether Ta1 stimulation promotes TRAF6 and p62 interaction, and whether association of PKCi/z with TRAF6 is functional. Cells were treated with Ta1 and immunoprecipitations were performed with either anti-TRAF6 or anti-PKCi/z antibodies, followed by IB analyses. Ta1 induced the interaction of TRAF6 with p62 (Fig 4B) . Phosphorylated PKCi/z was observed to associate with TRAF6 on Ta1 stimulation (Fig 4B) . Finally, we investigated whether Ta1 initiates IKK association with PKCi/z. Interestingly, interaction of PKCi/z with IKK was observed in untreated cells, and was not further potentiated by Ta1 treatment (Fig 4C) . Taken together, our data suggest that Ta1 induces formation of a signalsome, consisting of TRAF6, p62, PKCi/z and IKK.
DISCUSSION
Ta1 has been shown to induce expression of various cytokines by peripheral blood lymphocytes, including colony-stimulating factors, interferon-g, IL-2 and IL-7, and to stimulate maturation of thymocyte cells (reviewed by Billich, 2002) . The effects of Ta1 seem to be dependent on the presence of other mitogens or interferon, leading to the conclusion that Ta1 is not able to function as a classic primary signal in the induction of cytokines, (A) Mouse embryo fibroblasts (MEFs) were treated with Ta1 (100 ng/ml) for the indicated time points and then lysed. A 200 mg portion of lysates was incubated overnight with anti-PKCi/z or anti-TRAF2 antibodies together with 20 ml of protein A/G beads. The beads were washed four times with lysis buffer (0.2 M NaCl) and then co-immunoprecipitation of TRAF6 was assessed by immunoblotting (IB) analysis using an anti-TRAF6 antibody. IP, immunoprecipitation. (B) MEFs were treated with Ta1 (400 ng/ml) or IL-1 (20 ng/ml) for indicated durations. A 200 mg portion of cell lysates was incubated overnight with anti-PKCi/z, anti-TRAF6 or anti-TRAF4 antibodies together with 20 ml of protein A/G beads. The beads were washed four times with lysis buffer (0.2 M NaCl) and co-immunoprecipitation of p62, phospho-PKCi/z or TRAF6 was determined by IB analyses using anti-p62, anti-phospho-PKCi/z or anti-TRAF6 antibodies. (C) MEFs were treated with Ta1 (100 ng/ml), and 200 mg of cell lysates was incubated with an anti-PKCi/z antibody. Co-immunoprecipitation of IKK was detected by IB analysis using an anti-IKKa antibody. Our study shows that the TRAF6-IKK-NF-kB signalling pathway is involved in induction of IL-6 and IL-12 by Ta1. It has been well established that NF-kB has an important role in expression of a variety of immune genes, including cytokines, chemokines and lymphokines (Ghosh & Karin, 2002) . Disruption of IKKb or NF-kB severely impairs cytokine induction in response to viral and bacterial infections and blocks differentiation and maturation of immune cells (Ghosh & Karin, 2002) . Indeed, Tnfr À/À Ikkb À/À mice are more sensitive to the environment and survive 2 weeks or less after birth, until they succumb to opportunistic infections (Senftleben et al, 2001) . Thus, the finding of the physiological role of IKKb in the Ta1 pathway conforms with previous analyses of the NF-kB signalling pathway, which is of great importance in immune-cell function. Recently, a study showed that TRAF6 has a central role in DC maturation and development (Kobayashi et al, 2003) . Our results, indicating that Ta1 activates the TRAF6 pathway, will provide further insight into how Ta1 induces DC maturation.
MyD88, IRAK1 and TRAF6 are important intermediates in the TLR signalling pathway. Corroborating a recent study showing that Ta1 activates MyD88 (Romani et al, 2004) , our work indicates that both MyD88 and IRAK1 are primarily involved in activation of IKK by Ta1. Moreover, our observations suggest that Ta1 triggers TRAF6-dependent activation of PKCi/z, which in turn activates IKK. This notion is supported by evidence that phosphorylation of IKK or PKCi/z and activation of IKK by Ta1 are disrupted by lowering the levels of PKCz. Interestingly, TNFa is able to induce the association of TRAF6 and PKCi/z (Zhang et al, data not shown), suggesting a role for PKCi/z in the activation of IKK and NF-kB by TNFa. However, neither reducing nor abolishing the expression of PKCz in MEFs has an effect on activation of IKK by TNFa (Fig 3; Leitges et al, 2001 ). In contrast, the loss of PKCz in the lung severely impaired activation of IKK by TNFa and the TLR ligands IL-1 and LPS (Leitges et al, 2001) . Nevertheless, although differential roles of PKCz in the activation of IKK by TNFa in different cell types or tissues have been accredited to the levels of PKCz expression (Leitges et al, 2001) , the molecular mechanism of such a discrepancy is not well understood.
TLRs have been identified as receptors for exogenous microbial products (e.g. dsRNA, CpG-DNA and LPS) and endogenous factors (e.g. HSP60 and defensin b; Akira & Takeda, 2004) . It has been reported that Ta1 induces the expression of TLR2, TLR3, TLR5 and TLR9 in DCs (Romani et al, 2004) . Moreover, Ta1 augments induction of IL-12 in the response of DCs to CpG-ODN. Ta1 only stimulates IL-8 production in 293 cells overexpressing TLR9, but not TLR2 or TLR4, suggesting that TLR9 mediates the effect of Ta1 on DCs. However, TLR9 deficiency does not alter inhibition of fungal growth by Ta1. Conversely, the loss of MyD88 almost abolishes Ta1-induced protection of mice from fungal infection, indicating that MyD88 has an essential role in the Ta1 signalling pathway (Romani et al, 2004) . Therefore, it is still not clear which TLR is the receptor for Ta1, and how Ta1 activates TLRs remains to be explained further.
In conclusion, Ta1 activates the TRAF6-aPKC-IKK signalling pathway that leads to the activation of NK-kB, which in turn initiates cytokine gene expression. Our study provides a rationale for the therapeutic utility of Ta1, and explains further the pathways involved in its action.
METHODS
Plasmids, siRNA, Ta1, inhibitors and antibodies. Expression vectors encoding HA-IKKb (haemagglutinin), dnIRAK1, dnMyD88 and dnTRAF6 were described previously (Chu et al, 1999; Chuang et al, 2002) . PKCz siRNA and its control were purchased from Upstate (NY, USA). Ta1 and sTa1 peptides were synthesized (sequences have been described previously; Romani et al, 2004) and their endotoxin levels were o0.03 pg/ml, determined by a standard limulus lysate assay. The lyophilized powders were reconstituted in sterile endotoxin-free PBS. All regular antibodies were purchased from Santa Cruz Biotech (CA, USA) and antiphospho-antibodies were from Cell Signaling (MA, USA). Animals, cell cultures, transfection, Ta1 treatment, enzymelinked immunosorbent assays and RT-PCR. Ikkb À/À Tnfr1 À/À mice were generated as described previously (Chu et al, 2000; Senftleben et al, 2001) . C57BL6 mice were from Charles River (NY, USA). BMDMs were prepared as described previously (Chu et al, 2000) . Before use, BMDMs were seeded (2.5 Â 10 5 per well in triplicate) in 96-well plates and then treated with Ta1 or sTa1 (25-100 ng/ml). After 24 h, supernatant samples were collected and assessed for IL-6 and IL-12 using enzyme-linked immunosorbent assay kits (PharMingen, CA, USA). MEFs were cultured in DMEM supplemented with 10% FBS and antibiotics. Celltransfection experiments were performed using Lipofectamine plus reagents or Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, CA, USA). RT-PCR for IL-6 and IL-12 was performed as described previously (Chu et al, 2000) . PKCz siRNA transfection was performed according to the manufacturer's instructions (Upstate, NY, USA). Immunoprecipitation, kinase assays and immunoblotting assays. Lysates were prepared and incubated overnight with antibodies at 4 1C. Immunoprecipitates were washed and used for kinase assays. Kinase assays and IB analyses were performed as described previously (Chu et al, 2000) .
